top of page
gradientForSurfBreak.png

Item List

Oct 21, 2024
Businesswire
Epitel Expands AI Portfolio With A Fourth FDA 510(k) Clearance for REMI

Epitel, a leader in AI for patient-focused brain health technologies, announced today it received U.S. Food and Drug Administration (FDA) 510(k) clearance for REMI Vigilenz™ AI For Bedside Notifications. REMI Vigilenz AI For Bedside Notifications conducts an automated analysis of EEG data collected by the REMI™ wireless wearable EEG System in near real-time. Notifications occur when the algorithm recognizes seizure characteristics within a section of EEG.

Recent Posts

Portfolio Company

Carlsmed.png

Carlsmed Announces First aprevo® Bi-lateral Posterior Lumbar Interbody Fusion Pr ...

Carlsmed

Feb 10, 2026

Portfolio Company

Carlsmed.png

xCures and the Colorectal Cancer Alliance Partner to Support Patient Access and ...

The National Law Review

Feb 5, 2026

Portfolio Company

Carlsmed.png

Vanguards of Health Care: Carlsmed Personalizes Spine with AI ...

Bloomberg

Feb 5, 2026

surf break copy_edited_edited.jpg
surbreak-19.png
WM360_logo-18.png
bottom of page